Preferred Label : dolutegravir, rilpivirine drug combination;
MeSH synonym : dolutegravir - rilpivirine drug combination; dolutegravir and rilpivirine drug combination; dolutegravir-rilpivirine;
Origin ID : C000629908;
UMLS CUI : C4530989;
ATC code(s)
- Currated CISMeF NLP mapping
- MeSH term(s) associated for indexing
- Pharmacological action(s)
- Record concept(s)
- Semantic type(s)
- UMLS correspondences (same concept)
- Validated automatic mappings to BTNT
https://www.has-sante.fr/jcms/p_3293338/fr/juluca-50-mg/25-mg-rilpivirine-/-dolutegravir
2021
false
false
false
France
insurance, health, reimbursement
treatment outcome
dolutegravir, rilpivirine drug combination
dolutegravir
anti-hiv agents
dolutegravir and rilpivirine
hiv infections
HIV-1
adult
antiviral agents
pregnancy
HIV integrase inhibitors
reverse transcriptase inhibitors
evaluation of the transparency committee
---
https://www.has-sante.fr/portail/jcms/c_2869239/fr/juluca
https://www.has-sante.fr/portail/jcms/c_2869239/fr/juluca-dolutegravir/rilpivirine-association-d-antiviraux
2018
false
false
false
France
French
drug combinations
dolutegravir and rilpivirine
treatment outcome
HIV integrase inhibitors
reverse transcriptase inhibitors
hiv infections
HIV-1
adult
administration, oral
evaluation of the transparency committee
guidelines for drug use
dolutegravir
Rilpivirine
heterocyclic compounds, 3-ring
dolutegravir, rilpivirine drug combination
---
TIVICAY, TRIUMEQ and JULUCA (dolutegravir containing medicines) – Possible Risk of
Neural Tube Defects
Destinataires : Professionnels de la santé, y compris spécialistes des maladies infectieuses,
spécialistes du virus de l’immunodéficience humaine (VIH) et infirmiers(ères), virologues
cliniques, obstétriciens(ennes), gynécologues, pédiatres, spécialistes de la santé
sexuelle, pharmaciens(ennes) et omnipraticiens(ennes).
https://canadiensensante.gc.ca/recall-alert-rappel-avis/hc-sc/2018/66998a-fra.php
2018
false
false
false
Canada
French
English
pharmacovigilance note
neural tube defects
pregnancy
dolutegravir
dolutegravir
HIV integrase inhibitors
hiv infections
abnormalities, drug-induced
guidelines for drug use
pregnancy trimester, first
infant, newborn
administration, oral
drug combinations
lamivudine, abacavir and dolutegravir
dolutegravir and rilpivirine
heterocyclic compounds, 3-ring
dolutegravir, rilpivirine drug combination
Abacavir/Dolutegravir/Lamivudine
Rilpivirine
---
https://www.ema.europa.eu/medicines/human/EPAR/Juluca
2018
false
false
false
United Kingdom
French
English
syndication feed
summary of product characteristics
package leaflet
drug evaluation
Rilpivirine
dolutegravir
drug combinations
dolutegravir and rilpivirine
drug approval
europe
treatment outcome
HIV integrase inhibitors
HIV integrase inhibitors
reverse transcriptase inhibitors
reverse transcriptase inhibitors
hiv infections
HIV-1
adult
administration, oral
product surveillance, postmarketing
drug monitoring
drug interactions
pregnancy
breast feeding
drug evaluation, preclinical
dolutegravir
Rilpivirine
heterocyclic compounds, 3-ring
heterocyclic compounds, 3-ring
heterocyclic compounds, 3-ring
dolutegravir, rilpivirine drug combination
dolutegravir, rilpivirine drug combination
---
